Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass

International Journal of Cancer

Volumn 89, Issue 6, 2000, Pages 519-523

  Hgdall, Estrid V S ^a,b   Høgdall, Claus K ^b,c   Tingulstad, Solveig ^d   Hagen, Bjørn ^d   Nustad, Kjell ^e   Xu, Feng Ji ^f   Bast, Robert C ^f   Jacobs, Ian J ^g  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c Rigshospitalet   (Denmark)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; TETRANECTIN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BENIGN TUMOR; CANCER STAGING; COMPARATIVE STUDY; FEMALE; HUMAN; HUMAN TISSUE; OVARY CANCER; PELVIS TUMOR; PRIORITY JOURNAL;

EID: 0034693681     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20001120)89:6<519::aid-ijc9>3.0.co;2-%23     Document Type: Article

References (29)

1. Fibrin degration products and ovarian tumors
2. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer
3. Plasminogen activators, tissue degradation, and cancer
4. CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary
5. Transabdominal and transvaginal sonography of pelvic masses
6. A method of comparing the areas under receiver operating characteristic curves derived from the same cases
7. The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer
8. Plasma tetranectin and ovarian neoplasms
9. Preoperative plasma tetranectin as a prognostic marker in ovarian cancer patients
10. Plasma tetranectin and ovarian neoplasms
11. The use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second and third look operations for ovarian cancer
12. The role of serum tetranectin, CA 125 and a combined index as tumor markers in women with pelvic tumors
13. OVX1 radioimmunoassay results are dependent on the method of sample collection and storage
14. Screening for ovarian cancer
15. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer
16. Plasma tetranectin in healthy male and female individuals, measured by enzyme-linked immunosorbent assay
17. The fibrinolytic system: A key to tumor metastasis
18. Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses
19. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: First report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine
20. Fibrinolysis in human malignant tumors
21. Preoperative serum tumor-associated antigen levels in women with pelvic masses
22. Analytical and clinical performance of improved Abbott IMx CA 125 assay: Comparison with Abbott CA 125 RIA
23. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses
24. Serum assays in the management of ovarian carcinoma
25. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses
26. Elevation of multiple serum markers in patients with stage I ovarian cancer
27. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures
28. Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells
29. Pathways of coagulation/fibrinolysis activation in malignancy